Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company developing orally available small molecule therapeutics that modulate the neurotrophic hepatocyte growth factor (HGF) system to restore neuronal health and slow neurodegeneration. Its lead candidate, ATH-1105, targets neurodegenerative diseases like ALS by promoting neuroprotection, reducing inflammation, and enhancing nerve function. Athira leverages proprietary drug discovery, third-party manufacturing, and aims to address unmet needs in central and peripheral nervous system disorders.
This description was generated via AI from an annual report. Updated about 1 year ago.